Previous 10 | Next 10 |
-- Record Fourth-Quarter 2020 Net Sales of $745.3 Million Increased 105 Percent; Fourth-Quarter 2020 GAAP Net Income of $190.6 Million; Adjusted EBITDA of $371.0 Million -- -- Record Full-Year 2020 Net Sales of $2.20 Billion Driven by 110 Percent Growth in the Orphan Segme...
Horizon Therapeutics (NASDAQ:HZNP) is scheduled to announce Q4 earnings results on Wednesday, February 24th, before market open.The consensus EPS Estimate is $1.07 (+91.1% Y/Y) and the consensus Revenue Estimate is $692.84M (+90.6% Y/Y).Over the last 2 years, HZNP has beaten EPS estimates 100...
-- Results presented at NANOS 2021 Annual Meeting show persistent burden on physical and mental health -- Horizon Therapeutics plc (Nasdaq: HZNP) today announced results of a new Thyroid Eye Disease (TED) quality of life (QOL) assessment presented at the North American Neuro...
As per the latest 13F filing, Paulson & Co (John Paulson) added new positions in Thryv Holdings (THRY), Occidental Petroleum (OXY), American Equity Investment Life Holding (AEL), EQT (EQT) and Exxon Mobil (XOM).Positions are increased in Endo International (ENDP), Barrick Gold (GOLD) and ...
Horizon Therapeutics plc (Nasdaq: HZNP) announced today that its fourth-quarter and full-year 2020 financial results will be released on Wednesday, Feb. 24, 2021. Following the announcement, Horizon's management will host a live webcast at 8 a.m. Eastern Time to review the Company's fin...
Shares of Viela Bio (NASDAQ: VIE) were soaring Monday morning after it was announced that the biopharmaceutical company will soon be acquired by Horizon Therapeutics (NASDAQ: HZNP) . As of 11:27 a.m. EST, shares of Viela Bio were up by 52.5%. Horizon Therapeutics will ac...
Horizon Therapeutics plc (NASDAQ: HZNP) and Viela Bio, Inc. (NASDAQ: VIE) have entered into a definitive agreement where Horizon will acquire all issues and outstanding shares of Vielo Bio common stock for USD 53 per share in cash or a fully diluted equity value of USD...
Horizon Therapeutics (HZNP) and Viela Bio (VIE), up 24% premarket ink agreement under which Horizon will acquire all of the issued and outstanding shares of Viela Bio common stock for $53.00/share in cash, representing a fully diluted equity value of ~$3.05B.The transaction is expec...
- Conference Call Today at 8 a.m. EST to Discuss Transaction - - Provides TEPEZZA® (teprotumumab-trbw) Supply Update; Submitted Prior Approval Supplement to FDA to Support Increased Scale Production of TEPEZZA - Horizon Therapeutics plc (Nasdaq: HZNP) and Viela ...
HQH offers investors a managed quarterly distribution based on 2% of the NAV. The fund's discount has been tightening lately, but is still attractive for long-term investors. The healthcare exposure provides for a mixture of recession-resistant investments that worked especially w...
News, Short Squeeze, Breakout and More Instantly...
Horizon Therapeutics Public Limited Company Company Name:
HZNP Stock Symbol:
NASDAQ Market:
Horizon Therapeutics Public Limited Company Website:
Hitachi Construction Machinery Co. Ltd ADR (HTCMY) is expected to report for Q2 2024 DigitalBridge Group Inc. (DBRG) is expected to report $0 for Q3 2023 LY Corp ADR (YAHOY) is expected to report for Q2 2024 DT Midstream Inc. (DTM) is expected to report $0.9 for Q3 2023 Summit Mat...
Horizon Therapeutics Public Limited Company (HZNP) is expected to report $1.22 for Q3 2023
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION FOR IMMEDIATE RELEASE October 6, 2023 RECOM...